These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30673664)

  • 1. Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model.
    Miyake K; Kiyuna T; Li S; Han Q; Tan Y; Zhao M; Oshiro H; Kawaguchi K; Higuchi T; Zhang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Murakami T; Singh AS; Li Y; Nelson SD; Eilber FC; Bouvet M; Hiroshima Y; Chishima T; Matsuyama R; Singh SR; Endo I; Hoffman RM
    Chemotherapy; 2018; 63(5):278-283. PubMed ID: 30673664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
    Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
    Kawaguchi K; Higuchi T; Li S; Han Q; Tan Y; Igarashi K; Zhao M; Miyake K; Kiyuna T; Miyake M; Ohshiro H; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Singh SR; Eilber FC; Unno M; Hoffman RM
    Biochem Biophys Res Commun; 2018 Sep; 503(4):3086-3092. PubMed ID: 30166061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Murakami T; Li S; Han Q; Tan Y; Kiyuna T; Igarashi K; Kawaguchi K; Hwang HK; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Hiroshima Y; Lwin TM; DeLong JC; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Oncotarget; 2017 May; 8(22):35630-35638. PubMed ID: 28404944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Methioninase Combined With Tumor-targeting
    Igarashi K; Kawaguchi K; Zhao M; Han Q; Tan Y; Kiyuna T; Miyake K; Higuchi T; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2515-2523. PubMed ID: 32366396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase.
    Igarashi K; Li S; Han Q; Tan Y; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Apr; 119(4):3537-3544. PubMed ID: 29143983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago.
    Murakami T; Kiyuna T; Kawaguchi K; Igarashi K; Singh AS; Hiroshima Y; Zhang Y; Zhao M; Miyake K; Nelson SD; Dry SM; Li Y; DeLong JC; Lwin TM; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Cell Cycle; 2017 Jun; 16(11):1046-1052. PubMed ID: 28296559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyaki M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Singh AS; Chmielowski B; Nelson SD; Russell TA; Eckardt MA; Dry SM; Li Y; Singh SR; Chawla SP; Eilber FC; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2018 Dec; 506(4):912-917. PubMed ID: 30392912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
    Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
    Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.
    Higuchi T; Kawaguchi K; Miyake K; Han Q; Tan Y; Oshiro H; Sugisawa N; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Singh AS; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2018 Oct; 38(10):5639-5644. PubMed ID: 30275182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer.
    Hoffman RM; Murakami T; Kawaguchi K; Igarashi K; Tan Y; Li S; Han Q
    Methods Mol Biol; 2019; 1866():149-161. PubMed ID: 30725414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
    Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methioninase Cell-Cycle Trap Cancer Chemotherapy.
    Hoffman RM; Yano S; Igarashi K
    Methods Mol Biol; 2019; 1866():133-148. PubMed ID: 30725413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.
    Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake K; Miyake M; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Eckardt MA; Unno M; Eilber FC; Hoffman RM
    Cell Cycle; 2018; 17(3):356-361. PubMed ID: 29187018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model.
    Park JH; Han Q; Zhao M; Tan Y; Higuchi T; Yoon SN; Sugisawa N; Yamamoto J; Bouvet M; Clary B; Singh SR; Hoffman RM
    Tissue Cell; 2019 Dec; 61():109-114. PubMed ID: 31759402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model.
    Murakami T; DeLong J; Eilber FC; Zhao M; Zhang Y; Zhang N; Singh A; Russell T; Deng S; Reynoso J; Quan C; Hiroshima Y; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Chawla S; Endo I; Hoffman RM
    Oncotarget; 2016 Mar; 7(11):12783-90. PubMed ID: 26859573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.